导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.16% | 2756/4773 |
| 近一周 | -1.89% | 1839/5458 |
| 近一月 | -3.47% | 2118/5421 |
| 近一季 | -4.41% | 2334/5205 |
| 近半年 | -1.91% | 1946/4920 |
| 近一年 | 1.22% | 2560/4361 |
| 近两年 | 44.40% | 1729/2954 |
| 近三年 | 26.20% | 1244/2253 |
| 成立以来 | 200.94% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.73% 3374/4961 |
12.03% 2249/5312 |
- - |
- - |
| 2025 | 18.72% 2289/4813 |
-1.05% 2556/3635 |
2.07% 1902/4076 |
17.56% 2477/4524 |
- 2290/4813 |
| 2024 | 16.37% 821/3463 |
2.84% 689/2808 |
-1.08% 919/3014 |
16.81% 1343/3129 |
-2.08% 1948/3463 |
| 2023 | -9.02% 1089/2656 |
4.12% 1043/2280 |
-3.83% 922/2385 |
-2.76% 744/2515 |
-6.56% 1826/2655 |
| 2022 | -19.51% 859/2207 |
-14.10% 904/1919 |
6.45% 698/2016 |
-13.53% 916/2113 |
1.79% 1143/2208 |
| 2021 | -2.68% 867/1822 |
-3.03% 745/1255 |
4.47% 883/1330 |
-5.54% 819/1466 |
1.70% 831/1822 |
| 2020 | 28.06% 568/1250 |
-9.61% 695/1028 |
13.32% 628/1067 |
10.52% 540/1164 |
13.13% 391/1184 |
| 2019 | 35.57% 373/1092 |
26.60% 392/754 |
-0.37% 258/804 |
0.84% 452/850 |
6.59% 589/918 |
| 2018 | -22.39% 237/834 |
- - |
- - |
- - |
-11.50% 304/691 |
| 2017 | 22.49% 148/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.52% 248/605 |
- - |
- - |
- - |
- - |
| 2015 | 5.05% 225/575 |
- - |
- - |
- - |
- - |
| 2014 | 50.48% 82/237 |
- - |
- - |
- - |
- - |
| 2013 | -6.14% 109/186 |
- - |
- - |
- - |
- - |
| 2012 | 8.63% 50/140 |
- - |
- - |
- - |
- - |
| 2011 | -23.02% 57/102 |
- - |
- - |
- - |
- - |
| 2010 | -12.28% 33/58 |
- - |
- - |
- - |
- - |
| 2009 | 84.79% 14/27 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 广发沪深300ETF联接A VS. 长安沪深300非周期A(740101) |